Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

Summary

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This trial is a single-agent, single-arm, multicenter, open-label design clinical trial for advanced intrahepatic cholangiocarcinoma who have failed standard therapy. To evaluate the efficacy of VG161 administered by ultrasound or CT-guided intratumoral injection in patients with advanced intrahepatic cholangiocarcinoma, with the primary outcome measure being objective response rate (ORR).

Timeline

Start

2022-03-19

Primary completion

2025-09-30

Completion

2025-12-01

Drugs

Indications